Listening to the Data: Why There’s Room for Improvement in MI Care Heartscape® Consultants Meeting Charles V. Pollack, Jr, MA, MD, FACEP, FAAEM, FAHA Chairman,

Slides:



Advertisements
Similar presentations
ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network) Initial Report 1st Quarter 2007 Results Report prepared by: www. ncdr.com.
Advertisements

Patient Oriented Therapy Non STE ACS
The prevalence of use of beta- blockers in secondary prevention of myocardial infarctions in patients hospitalized 1 Institute of Epidemiology and biostatistics,
NAPLES II Novel Approaches for Preventing or Limiting Event Study Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction.
How to Use Heart Rate Changes to Improve Exercise Test Results V. Froelicher, MD Professor of Medicine Stanford University VA Palo Alto HCS.
© 2010, American Heart Association. All rights Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality.
Approach to The Low Risk Chest Pain Patient John P Erwin, III, MD, FACC, FAHA Associate Professor of Medicine Scott and White Heart and Vascular Institute.
NCEP ATP IV GuidelineS: 2013 Update
Utilization of Cardiac Serum Marker Measurements to Identify and Exclude Acute Myocardial Infarction Francis M. Fesmire, MD, FACEP Assistant Professor,
Risk stratification and medical management of NSTE-ACS (UA/NSTEMI )
1 GRASP-AF Audit - Intro 8 th July 2010 Mark Gregory.
Acute Coronary Syndromes Jason Ryan, M.D.. Acute Coronary Syndromes Unstable Angina + Non-ST-Elevation MI + ST-Elevation MI Acute Coronary Syndromes (ACS)
Charles V. Pollack, Jr., M.A., M.D., FACEP, FAHA
Screening and diagnosis of AF and stratifying stroke risk.
CV Health: Three Ways to ‘kNOw’
Improving Office Care for Chest Pain Thomas D. Sequist, MD MPH Associate Professor of Medicine and Health Care Policy Brigham and Women ’ s Hospital, Division.
BASE HOSPITAL GROUP ONTARIO Chapter 3 for 12 Lead Training -WHY 12 LEAD- Ontario Base Hospital Group Education Subcommittee 2008 TIME IS MUSCLE.
Cardiovascular Risk Assessment in Women
Ischaemic Heart Disease- Implications of Gender Dr Kaye Birks School of Rural Health Monash University Australia Gender Competency Training for Medical.
Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K
The 80 Lead ECG Body Surface Map: Can We Detect More STEMI Than with a 12 Lead ECG? James Hoekstra MD Professor and Chairman Department of Emergency Medicine.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
Acute Coronary Syndromes Clinical Care Standard An introduction for clinicians and health services.
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
OPTIMAL UPSTREAM ANTITHROMBIN THERAPY IN NSTE ACS PATIENTS MANAGED IN THE CARDIAC CATH LAB: DOES IT MATTER WHICH AGENT IS STARTED IN THE ED? Charles V.
Acute Coronary Syndrome. Acute Coronary Syndrome (ACS) Definition of ACS Signs and symptoms of ACS Gender and age related difference in ACS Pathophysiology.
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
Acute Coronary Syndromes
Safety and Effectiveness of Bivalirudin in NSTE ACS by duration of the upstream infusion in the ACUITY trial: Implications for ED and upstream management.
Myocardial Ischemia Redefined: Optimal Care in CAD.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ACS Clinical Pathway. Who? Pts with Acute Ischemic Heart Disease now described as having ACS.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
Enoxaparin – Future Prospects in Cardiovascular Diseases David Hasdai, MD Rabin Medical Center Tel Aviv University.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
Acute Coronary Syndrome David Aymond, MD. ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS.
Antiplatelet Interventions in Acute Coronary Syndromes.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
BACKGROUND: COMPARATIVE ANALYSIS OF MORPHOLOGICAL EKG CHANGES AND DOOR-TO-BALLOON TIME IN STEMI Mercy P. Chandrasekaran, Jeffrey Cook, Raj Marok, Carlos.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Acute Coronary Syndrome
Atherosclerotic Cardiovascular Heart Disease in Women
Women and Cardiovascular Disease
Prehospital NSTEMI Patient Assessment and Treatment
Risk Stratification of Chest Pain: Best Practices
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Clinical need for determination of vulnerable plaques
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
This series of slides highlights a report on a symposium at the European Society of Cardiology Congress held in Munich, Germany from August 28 to September.
Section A: Introduction
European Heart Association Journal 2007 April
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,
Section F: Clinical guidelines
The European Society of Cardiology Presented by RJ De Winter
Early Management of NSTE-ACS: From the ED to the Cath Lab
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Global Registry of Acute Coronary Events: GRACE
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Nat. Rev. Cardiol. doi: /nrcardio
Study flow chart and diagnosis at discharge from ED
Presentation transcript:

Listening to the Data: Why There’s Room for Improvement in MI Care Heartscape® Consultants Meeting Charles V. Pollack, Jr, MA, MD, FACEP, FAAEM, FAHA Chairman, Department of Emergency Medicine Pennsylvania Hospital Professor of Emergency Medicine University of PennsylvaniaSchool of Medicine University of Pennsylvania School of Medicine Philadelphia, PA Charles V. Pollack, Jr, MA, MD, FACEP, FAAEM, FAHA Chairman, Department of Emergency Medicine Pennsylvania Hospital Professor of Emergency Medicine University of PennsylvaniaSchool of Medicine University of Pennsylvania School of Medicine Philadelphia, PA

Antman EM, Hand M, Armstrong PW, et al Focused update of the ACC/AHA 2004 guidelines for the management of patients ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol and Circulation; at and Pollack CV, Antman EA, Hollander JE: 2007 Focused update to the ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: Implications for emergency department practice. Ann Emerg Med 2008, in press. STEMI: Optimal Therapy, 12/12/07

Anderson JL, Adams CD, Antman EM, et al guidelines for the management of patients with unstable angina/non-ST-segment-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007;50:e1-e157, and Circulation 2007;116:e148-e304, and at and at Pollack CV, Braunwald E: 2007 Update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Implications for emergency department practice. Ann Emerg Med 2008;51: NSTE ACS: Optimal Therapy, 8/6/07

STEMI diagnosis is clinical + ECG; markers not necessary there is risk stratification within STEMI, but in general, STEMI is high-risk treatment focus is on opening the IRA as soon as possible Necessary components: clinical recognition accurate ECG interpretation rapid treatment response STEMI vs NSTE ACS

NSTEMI diagnosis is clinical + markers; ECG Δs not necessary and often irrelevant risk stratification driven by biomarkers: elevated troponin = elevated risk treatment focus is on medical stabilization and early (24-48h) intervention Necessary components: clinical recognition accurate ECG interpretation (exclude STEMI) consistent treatment response STEMI vs NSTE ACS

Unstable angina diagnosis is clinical; ECG Δs not necessary and markers are negative by definition ST-segment depression confers somewhat higher risk and more likely to benefit from more aggressive therapy treatment focus is on medical stabilization and further evaluation Necessary components: clinical recognition consistent care and treatment STEMI vs NSTE ACS

clinical recognition reliance on ECG (as a rule-in or as a rule-out) timely evaluation and treatment consistent care STEMI vs NSTE ACS: Commonality

clinical recognition reliance on ECG (as a rule-in or as a rule-out) timely evaluation and treatment consistent care STEMI vs NSTE ACS: Commonality

We Must Risk Stratify Patients with Chest Pain Three levels of risk strat are pertinent to the ED: low, intermediate, or high risk that ischemic symptoms are a result of CAD low, intermediate, or high risk of short-term death or nonfatal MI from ACS dynamic, ongoing risk-oriented evaluation of low- or intermediate-risk patients for “conversion” to high- risk status that is linked to intensity of treatment Three levels of risk strat are pertinent to the ED: low, intermediate, or high risk that ischemic symptoms are a result of CAD low, intermediate, or high risk of short-term death or nonfatal MI from ACS dynamic, ongoing risk-oriented evaluation of low- or intermediate-risk patients for “conversion” to high- risk status that is linked to intensity of treatment Pollack CV. Ann Emerg Med 2001;38:229

up to one-third of ACS patients present without chest pain of these, 2/3 are NSTE ACS and 1/3 are STEMI particularly prevalent in women, diabetics, and patients with a history of heart failure “atypical is the new typical” as we see older and older patients, but atypical presentations are classically associated with delayed diagnosis and treatment Clinical Recognition of ACS Canto J et al, JAMA 2000; 283:3223

Clinical Recognition of ACS Drives Tx Canto J et al, JAMA 2000; 283:3223 Each comparison p < 0.001

Risk Scores TIMI GRACE PURSUIT ACI-TIPI Goldman best used to supplement—not replace—clinical judgment less useful in atypical presentations, but indeed validated in an ED population... Clinical Recognition of ACS

/123456/7 D/MI/Urg 14d (%) D/MI/Urg Revasc 14d (%) Risk Factors Risk Factors Risk Level LOW INTERMEDIATE HIGH UFH Group TIMI 11B (N= 1957) TIMI risk score for UA/NSTEMI Antman EM et al. JAMA 2000; 284:

TIMI risk score for UA/NSTEMI Pollack CV et al. Acad Emerg Med 2006;13: /123456/7 D/MI/Urg 30d (%) D/MI/Urg Revasc 30d (%) Risk Factors Risk Factors Risk Level LOW INTERMEDIATE HIGH

Validation and treatment interaction for enoxaparin (ESSENCE data) Risk factors % Triple endpoint (14d) UFH Enoxaparin Total0/123456/7 population p=0.02  2 for trend p<0.001  2 for trend Antman EM at al, JAMA 2000;284:835

clinical recognition reliance on ECG (as a rule-in or as a rule-out) timely evaluation and treatment consistent care STEMI vs NSTE ACS: Commonality

ECG   Carries diagnostic and prognostic value   Especially valuable if captured during pain   ST-segment depression or transient ST-segment elevation are primary ECG markers of UA/NSTEMI   up to 25% of patients with NSTEMI and +marker develop Q-wave MI; 75% have NSTEMI   only classifying differentiation between UA and NSTEMI is a positive biomarker   inverted T-waves suggestive of ischemia, particularly with good chest pain story   Carries diagnostic and prognostic value   Especially valuable if captured during pain   ST-segment depression or transient ST-segment elevation are primary ECG markers of UA/NSTEMI   up to 25% of patients with NSTEMI and +marker develop Q-wave MI; 75% have NSTEMI   only classifying differentiation between UA and NSTEMI is a positive biomarker   inverted T-waves suggestive of ischemia, particularly with good chest pain story

ECG   Generally more useful in identifying STEMI than UA/NSTEMI   GLs suggest that serial ECGs increase both sensitivity and specificity   GLs withhold recommendation on utility of continuous ST-segment monitoring   GLs recommend mathematical models based on ECG findings only for identification of patients at low risk and for prognosis in those with ischemia   Generally more useful in identifying STEMI than UA/NSTEMI   GLs suggest that serial ECGs increase both sensitivity and specificity   GLs withhold recommendation on utility of continuous ST-segment monitoring   GLs recommend mathematical models based on ECG findings only for identification of patients at low risk and for prognosis in those with ischemia

ECG: Limitations   Only a point-in-time sample  Most common ECG in NSTE ACS is NSSTTΔs  In i*trACS, more than half of initial ECGs in patients with evolving MIs were nondiagnostic

ECG: Limitations   Large portions of myocardium are missed or at best are indirectly seen   Posterior wall   RV   High lateral   Addressed with   Additional leads   Not often done... Not often done correctly... Not enough “coverage”   Large portions of myocardium are missed or at best are indirectly seen   Posterior wall   RV   High lateral   Addressed with   Additional leads   Not often done... Not often done correctly... Not enough “coverage”

ECG: Limitations   Difficulties in interpretation   BBB   LVH   Early repolarization   Pericarditis   Inexperienced reader   Addressed with   Computerized interpretations   Consultation   Training   Risk management   Difficulties in interpretation   BBB   LVH   Early repolarization   Pericarditis   Inexperienced reader   Addressed with   Computerized interpretations   Consultation   Training   Risk management

clinical recognition reliance on ECG (as a rule-in or as a rule-out) timely evaluation and treatment consistent care STEMI vs NSTE ACS: Commonality

STEMI D2B target 90 minutes new data suggest that the likelihood of achieving TIMI-3 flow after PPCI is decreased by 21% (95% CI, 10-31%) with every 60min ischemic time* likelihood of achieving optimal (TMPG 2/3) reperfusion after PPCI is decreased by 19% (4-31%) with every 60min ischemic time* TMPG 2/3 associated with reduced 90day mortality D2N target 30 minutes STEMI vs NSTE ACS: Time, Time, Time * Brener SJ et al, Eur Heart J 2008;29:1127

NSTE ACS (high risk) 2000 ACC/AHA GLs: inpatient evaluation recommended (I-C) 2002 ACC/AHA GLs: diagnostic cath recommended within 48h (I-A) 2007 ACC/AHA GLs: diagnostic cath recommended within 4-24h (I-A) STEMI vs NSTE ACS: Time, Time, Time

Time to treatment is dependent on time to diagnosis, and accuracy of diagnosis ECG within 10 minutes accuracy not addressed markers within 60 minutes proper patients for assay must first be identified Public reporting of times has increased pressure on providers (image, P4P, medicolegal risk) and led to unusual interpretations of efficiency of care STEMI vs NSTEMI PPCI vs lysis STEMI vs NSTE ACS: Time, Time, Time

clinical recognition reliance on ECG (as a rule-in or as a rule-out) timely evaluation and treatment consistent care STEMI vs NSTE ACS: Commonality

UMass STEMI %DTB < 90 minutes vs Mortality Courtesy of Greg Volturo, MD

Hospital Link Between Overall Guidelines Adherence and Mortality: NSTE-ACS Peterson ED et al, JAMA 2006;295:1863 Every 10%  in guidelines adherence  10%  in mortality (OR=0.90, 95% CI: )

Conclusions ► ► ACS evaluation is complicated by atypical presentations, concern over medicolegal risk, inadequate collaboration across disciplines, and public reporting/P4P issues ► ► Atypical presentations are increasingly common ► ► Electrocardiography, the traditional ED triage point for emergent vs urgent therapy, is limited by time, geography, and reading expertise ► ► Patient care and outcomes may be significantly hampered by these issues ► ► ACS evaluation is complicated by atypical presentations, concern over medicolegal risk, inadequate collaboration across disciplines, and public reporting/P4P issues ► ► Atypical presentations are increasingly common ► ► Electrocardiography, the traditional ED triage point for emergent vs urgent therapy, is limited by time, geography, and reading expertise ► ► Patient care and outcomes may be significantly hampered by these issues